Immutep Company Overview
Cutting-edge Immunotherapy Treatments
Immutep is leading the development of immunotherapy for cancer and autoimmune diseases.
Leadership in LAG-3 Immunotherapy
We are global leaders in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or "LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by our Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting Immutep at the forefront of immunotherapy drugs for cancer and autoimmune diseases.
Our objective is to harness and strengthen the power of the body’s own immune systems through therapeutic intervention for the benefit of patients’ health. This is how immunotherapy fights cancer and autoimmune disease.
Our LAG-3 Immunotherapy Product Candidates
We have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.
Our lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) for various cancer indications.
- IMP321, known as eftilagimod alpha - immunotherapy for cancer
- IMP761 - preclinical immunotherapy for autoimmune disease
- IMP701, known as LAG525 - immunotherapy for solid tumors, blood cancer and breast cancer (partnered with Novartis)
- IMP731, known as GSK‘781 - immunotherapy in ulcerative colitis (partnered with GSK)
Immutep is listed on the Australian Stock Exchange (IMM) and on the NASDAQ Global Market (IMMP) in the U.S. (ADR's).